izalontamab brengitecan (BL-B01D1) - Biokin Pharma, BMS
Izalontamab brengitecan: Data readout from P2/3 IZABRIGHT-Breast01 trial (NCT06926868) for 1L TNBC in 2028 (Bristol-Myers Squibb) - Apr 24, 2025 - Q1 2025 Results 
P2/3 data • Breast Cancer • Oncology • Triple Negative Breast Cancer
https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2025/BMY-2025-Q1-Results-Investor-Presentation-with-Appendix.pdf
 
Apr 24, 2025
 
 
a210e3fc-4909-402d-aad0-5a49c898367b.png